Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Small study tests High-Dose antibiotic for sepsis

NCT ID NCT07245966

Knowledge-focused Sponsor: Prince of Songkla University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study looked at how a high dose of the antibiotic ceftriaxone works in 20 adults with sepsis. Researchers measured drug levels in the blood to see if the dose was strong enough to kill bacteria. The goal was to find the best dose to improve survival in sepsis patients.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ceftriaxone (a broad-spectrum antibiotic)
What this could lead to
If successful, this could help doctors choose the right dose of ceftriaxone for sepsis patients, potentially improving survival.
What could go wrong
This was a very small study (20 people) that only measured drug levels, not patient outcomes. The results may not apply to all sepsis patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

20 people

The number who actually took part.

Started

Jun 2024

Finished

Feb 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

20 people in total

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participants aging over 18 years old with the symptoms of systemic inflammatory response syndrome (SIRS) which requires at least two of the following symptoms * Temperature over 38 degree Celsius (Fever) or lower than 36 degree Celsius (hypothermia) * Tachycardia * Tachypnea, or the detection of PaCO2 under 32 mmHg, or hypocapnia due to hyperventilation * Participants are about to received Ceftriaxone by the physician * Weighting equal to or more than 50 kg Exclusion Criteria: * Patients with the clinical record of the severe allergy to β-lactam or Ceftriaxone * Patients received Ceftriaxone within 3 days before the participation * Having a culture result of being resistant to Ceftriaxone * Having CLcr lower than 50 ml/min, or receiving hemodialysis, or renal replacement therapy * Meningitis patients * Decompensated liver disease * Pregnant and lactating * Septic shock patients * Having the level of serum albumin lower than 2.5 g/dl

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Sepsis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

infectious disease with sepsis Sepsis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Sepsis

Contacts and locations

Locations

  • Faculty of Medicine, Prince of Songkla University

    Hat Yai, Changwat Songkhla, 90110, Thailand

More trials for these conditions

Other studies related to the condition(s) this trial covers.